Global Health Limited (MEDANTA) Fair Value & Analysis
Healthcare · IN · Market cap ₹364B
Strengths
Risks
Fair value as of: Aug 13, 2026
From 16 valuation models · updated 8 days ago
Share price +4.2% over the past month.
A solid business, but screening 69% overvalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (₹548.60). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
45‑month range ₹414.00 – ₹1,487 · fair‑value band ₹328.27 – ₹548.60 · the ₹1,410 price screens above the ₹438.44 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Global Health Limited (MEDANTA) currently trades at ₹1,410, while our model-based Fair Value estimate is ₹438.44, implying the stock looks roughly 68.9% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Global Health Limited generated revenue of ₹44.1B at a net margin of 12.6%. Revenue grew 24.5% year over year. It earns a return on equity of 15.0%. Net debt stands at ₹598M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹328.27 (bear case) to ₹548.60 (bull case); at ₹1,410, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 3% below its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at -69%, MEDANTA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (₹573.41) versus Dividend Discount (₹8.60). Highest evidence: Residual Income (76).
Notify me when MEDANTA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 66
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and …
Full company description
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Global Health Limited reported revenue of ₹44.1B in FY2026 versus ₹21.7B in FY2022, a compound +19.4%/yr. Reported net income was ₹5.6B in FY2026, compounding +29.8%/yr from FY2022.
MEDANTA screens 69% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 268 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.09 | R$47.31 | +43% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | -66% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.40 THB | 18.57 THB | -4% |
| Fortis Healthcare Limited FORTIS | ₹906.15 | ₹300.29 | -67% |
Compare Global Health Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Global Health Limited (MEDANTA) overvalued or undervalued?
What is the fair value of MEDANTA?
What is the quality score of MEDANTA?
What is the revenue of Global Health Limited (MEDANTA)?
What is the net profit margin of MEDANTA?
Does Global Health Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Global Health Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.